This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

A Legit Reason To Give Amicus' Fabry Drug Another Chance

The results for the 25 Fabry patients with baseline GL-3 levels of 0.3 or higher -- more severe, and measurable disease -- tell a different story. Here, 64% of patients (7/11) treated with Amigal were classified as a responder compared to 14% of patients (2/14) treated with a placebo. The separation in response rates between Amigal and placebo continues for GL-3 cut points above 0.3 as well.

Amicus designed the phase III study to meet its primary endpoint based on the assumption of a 60-70% response rate in the Amigal arm compared to a 20% or less response rate in the placebo arm. In other words, the study would have succeeded had the overall patient population resembled the 25 patients with baseline GL-3 levels of 0.3 or higher, Amicus believes.

At this point, you should be wondering skeptically if Amicus just picked this GL-3 level cut-off level of 0.3 because it makes the Amigal data look the best. The company says it did not, adding that FDA and independent pathologists have all agreed previously that a GL-3 level of 0.3 represents a starting point for measurable, clinically meaningful Fabry disease. The only reason Amicus didn't exclude patients with GL-3 levels below 0.3 was that kidney biopsies are not routinely performed to screen patients for clinical trials. Amicus tried to use urine levels of GL-3 as a surrogate marker for higher disease burden but it proved to be too permissive.

Looking ahead, Amicus hopes to bolster its argument supporting Amigal's efficacy with an analysis of the trial after 12 months of treatment. The best case for the company would be if patients treated with a full 12 months of Amigal maintain the the response rate observed at six months, or improve further.

According to the study design, placebo patients crossed over to receive Amigal at six months. Amicus hopes to show that the response rates for the placebo-delayed treatment patients at 12 months look similar to the six-month results recorded by the original Amigal-treated patients.

If that happens, Amicus and its partner GlaxoSmithKline (GSK) expect to seek U.S. Approval for Amigal despite the study failing to hit its primary endpoint. Amicus believes FDA will look at the totality of the data, including the benefit seen in patients with more measurable disease.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
3 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,039.49 +60.36 0.36%
S&P 500 1,992.37 +5.86 0.30%
NASDAQ 4,532.1040 +5.6220 0.12%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs